State-Of-The-Art Human Gene Therapy: Part II. Gene Therapy Strategies and Clinical Applications

被引:0
|
作者
Wang, Dan [1 ]
Gao, Guangping [1 ,2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China
基金
美国国家卫生研究院;
关键词
LEBER CONGENITAL AMAUROSIS; ENGINEERED NUCLEASES; IMMUNE-RESPONSES; RPE65; MUTATIONS; VECTORS; PROGRESS; AUGMENTATION; CONSTRUCTS; PROTECTION; INFECTION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In Part I of this Review (Wang and Gao, 2014), we introduced recent advances in gene delivery technologies and explained how they have powered some of the current human gene therapy applications. In Part II, we expand the discussion on gene therapy applications, focusing on some of the most exciting clinical uses. To help readers to grasp the essence and to better organize the diverse applications, we categorize them under four gene therapy strategies: (1) gene replacement therapy for monogenic diseases, (2) gene addition for complex disorders and infectious diseases, (3) gene expression alteration targeting RNA, and (4) gene editing to introduce targeted changes in host genome. Human gene therapy started with the simple idea that replacing a faulty gene with a functional copy can cure a disease. It has been a long and bumpy road to finally translate this seemingly straightforward concept into reality. As many disease mechanisms unraveled, gene therapists have employed a gene addition strategy backed by a deep knowledge of what goes wrong in diseases and how to harness host cellular machinery to battle against diseases. Breakthroughs in other biotechnologies, such as RNA interference and genome editing by chimeric nucleases, have the potential to be integrated into gene therapy. Although clinical trials utilizing these new technologies are currently sparse, these innovations are expected to greatly broaden the scope of gene therapy in the near future.
引用
收藏
页码:151 / 161
页数:11
相关论文
共 50 条
  • [21] Clinical applications of gene therapy
    Carter, BJ
    Kohn, DB
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 1999, 1 (04) : 420 - 421
  • [22] Gene therapy: Strategies in applications.
    Hallez, S
    REVUE DES MALADIES RESPIRATOIRES, 1995, 12 (06) : 567 - 583
  • [23] State of the art: gene therapy of haemophilia
    Spencer, H. T.
    Riley, B. E.
    Doering, C. B.
    HAEMOPHILIA, 2016, 22 : 66 - 71
  • [24] GENE THERAPY FOR THALASSEMIA: STATE OF THE ART
    Lidonnici, M. R.
    Aprile, A.
    Rossi, C.
    Mandelli, G.
    Tiboni, F.
    Cappellini, M. D.
    Aiuti, A.
    Marktel, S.
    Ciceri, F.
    Ferrari, G.
    HAEMATOLOGICA, 2015, 100 : 203 - 204
  • [25] Gene Therapy in Ophthalmology: State of the Art
    Kovtun, A.
    Epple, M.
    Steuhl, K. P.
    Erguen, S.
    Fuchsluger, T.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2012, 229 (06) : 603 - 607
  • [26] Gene therapy: State of the art and perspectives
    Hantzopoulos, PA
    Gansbacher, B
    CHIRURG, 1996, 67 (10): : 980 - 983
  • [27] Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease
    Douglas, Michael R.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (06) : 695 - 705
  • [28] Photodynamic therapy with NIR-II probes: review on state-of-the-art tools and strategies
    Yang, Yiqian
    Jiang, Shaohua
    Stanciu, Stefan G.
    Peng, Hao
    Wu, Aiguo
    Yang, Fang
    MATERIALS HORIZONS, 2024, 11 (23) : 5815 - 5842
  • [29] Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art
    Bondi, Maria Luisa
    Craparo, Emanuela Fabiola
    EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (01) : 7 - 18
  • [30] Gene Therapy Strategies in Bone Tissue Engineering and Current Clinical Applications
    Atasoy-Zeybek, Aysegul
    Kose, Gamze Torun
    CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 4: STEM CELLS AND CELL BASED STRATEGIES IN REGENERATION, 2018, 1119 : 85 - 101